Latest Period
Q1 2026
Security Snapshot
Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) Institutional Ownership
CUSIP: 92764N102
13F Institutional Holders and Ownership History from Q4 2019 to Q1 2026
Institutions Reporting
250
Shares (Excl. Options)
139,483,767
Price
$8.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Symbol
- VIR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 139,483,767
- Total 13F value
- $1,248,624,974
- Portfolio coverage rank
- 0%
- Share change
- +19,653,694
- Value change
- +$201,072,475
- Number of holders
- 250
- Shares outstanding
- 168,432,200
- SEC-reported price per share
- $9.29
- Insider filing price
- $9.29
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VIR - Vir Biotechnology, Inc. - Common Stock, $0.0001 par value is tracked under CUSIP 92764N102.
- 250 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 218 to 250 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $696,533,329 to $1,248,624,974.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 250 institutions filings for Q1 2026.
Security key
92764N102
Latest holder period
Q1 2026
13F holders
250
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
VIR full holder history
Vir Biotechnology, Inc. SEC filings
Vir Biotechnology, Inc. company facts
Vir Biotechnology, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92764N102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
VIR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | $93,255,785 | 14,826,039 | BlackRock, Inc. | 31 Mar 2025 | |||
| ARCH Venture Fund IX, L.P. | 8.5% | $101,645,627 | 13,534,704 | Robert Nelsen | 27 Feb 2026 | |||
| SB INVESTMENT ADVISERS (UK) LTD | 6.5% | -32% | $118,567,847 | -$23,489,014 | 10,948,093 | -17% | SB Investment Advisers (UK) Limited | 31 Mar 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.8% | $82,944,826 | 9,257,235 | Vanguard Portfolio Management | 31 Mar 2026 |
As of 31 Mar 2026, 250 institutional investors reported holding 139,483,767 shares of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR). This represents 83% of the company’s total 168,432,200 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
64%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11% | 17,998,329 | +10% | 0% | $161,265,028 |
| ARCH Venture Management, LLC | 7.7% | 12,916,663 | 0% | 17% | $115,733,300 |
| SB INVESTMENT ADVISERS (UK) LTD | 6.5% | 10,948,093 | -17% | 1.3% | $98,094,913 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | 9,215,577 | 0% | 0% | $82,571,570 |
| GSK plc | 5.1% | 8,550,954 | 0% | 13% | $76,616,548 |
| STATE STREET CORP | 4.2% | 7,141,094 | +15% | 0% | $63,984,202 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 5,382,103 | 0% | 0% | $48,223,643 |
| GOLDMAN SACHS GROUP INC | 1.9% | 3,250,227 | +107% | 0% | $29,122,034 |
| MORGAN STANLEY | 1.7% | 2,854,205 | +6.5% | 0% | $25,573,682 |
| ADAR1 Capital Management, LLC | 1.6% | 2,744,714 | 1.5% | $24,592,637 | |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 2,657,843 | +14% | 0% | $23,819,795 |
| DIMENSIONAL FUND ADVISORS LP | 1.5% | 2,579,678 | +1.7% | 0% | $23,107,432 |
| CITADEL ADVISORS LLC | 1.2% | 2,098,476 | +329% | 0.01% | $18,802,345 |
| FMR LLC | 1.2% | 2,071,848 | -34% | 0% | $18,563,762 |
| Soleus Capital Management, L.P. | 1.2% | 2,002,000 | 0.73% | $17,937,920 | |
| Point72 Asset Management, L.P. | 1.2% | 1,952,234 | +897% | 0.03% | $17,492,017 |
| Boxer Capital Management, LLC | 1.1% | 1,866,000 | +199% | 2.2% | $16,719,360 |
| GordonMD Global Investments LP | 0.9% | 1,518,552 | +63% | 12% | $13,606,226 |
| Sio Capital Management, LLC | 0.89% | 1,498,620 | +213% | 1.9% | $13,427,635 |
| Pictet Asset Management Holding SA | 0.88% | 1,480,828 | +10879% | 0.01% | $13,268,219 |
| Hudson Bay Capital Management LP | 0.87% | 1,469,510 | +11% | 0.08% | $13,166,810 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0.86% | 1,442,336 | 0.05% | $12,923,331 | |
| TWO SIGMA INVESTMENTS, LP | 0.85% | 1,439,494 | +144% | 0.01% | $12,897,866 |
| Qube Research & Technologies Ltd | 0.74% | 1,248,669 | +1403% | 0.02% | $11,188,074 |
| Clearstead Advisors, LLC | 0.72% | 1,216,400 | 0.1% | $10,898,944 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Latest
Q1 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 139,483,767 | $1,248,624,974 | +$201,072,475 | $8.96 | 250 |
| 2025 Q4 | 115,546,439 | $696,533,329 | -$6,968,165 | $6.03 | 218 |
| 2025 Q3 | 107,007,241 | $610,804,612 | -$19,864,830 | $5.71 | 209 |
| 2025 Q2 | 110,838,661 | $558,775,027 | +$84,580,503 | $5.04 | 211 |
| 2025 Q1 | 93,307,654 | $604,780,740 | +$27,869,791 | $6.48 | 230 |
| 2024 Q4 | 88,707,515 | $651,126,620 | +$14,506,884 | $7.34 | 202 |
| 2024 Q3 | 87,600,991 | $656,230,226 | -$4,592,687 | $7.49 | 195 |
| 2024 Q2 | 88,056,992 | $783,680,407 | -$9,558,987 | $8.90 | 213 |
| 2024 Q1 | 88,814,549 | $899,654,431 | +$7,160,790 | $10.13 | 205 |
| 2023 Q4 | 88,171,139 | $887,025,787 | +$1,493,653 | $10.06 | 202 |
| 2023 Q3 | 88,255,499 | $826,977,393 | -$227,669,705 | $9.37 | 212 |
| 2023 Q2 | 90,761,353 | $2,226,351,489 | +$60,012,170 | $24.53 | 222 |
| 2023 Q1 | 88,385,448 | $2,056,730,043 | +$54,021,550 | $23.27 | 226 |
| 2022 Q4 | 86,118,572 | $2,179,650,166 | -$15,704,818 | $25.31 | 219 |
| 2022 Q3 | 86,915,381 | $1,675,900,472 | -$11,606,508 | $19.28 | 208 |
| 2022 Q2 | 86,086,454 | $2,193,070,491 | +$146,002,800 | $25.47 | 201 |
| 2022 Q1 | 81,103,450 | $2,086,374,530 | -$14,155,763 | $25.72 | 191 |
| 2021 Q4 | 78,095,522 | $3,252,220,942 | +$158,691,641 | $41.87 | 203 |
| 2021 Q3 | 74,464,481 | $3,240,626,324 | -$19,547,865 | $43.52 | 169 |
| 2021 Q2 | 74,156,851 | $3,506,017,317 | +$66,755,814 | $47.28 | 156 |
| 2021 Q1 | 75,409,279 | $3,865,770,922 | -$99,056,866 | $51.27 | 151 |
| 2020 Q4 | 76,141,156 | $2,039,280,477 | +$150,971,873 | $26.78 | 136 |
| 2020 Q3 | 70,048,123 | $2,405,706,821 | +$553,884,772 | $34.33 | 117 |
| 2020 Q2 | 53,528,634 | $2,192,860,452 | +$657,421,714 | $40.97 | 109 |
| 2020 Q1 | 37,861,951 | $1,297,525,769 | -$4,041,452 | $34.27 | 61 |